648905-68-4

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzenesulfonic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, 2,2-dimethylpropyl ester is used as an intermediate in the synthesis of 5-Amino-3-(4-sulfonylphenyl)salicyclic Acid Sodium Salt (A629340), an impurity of mesalamine (M258100). Mesalamine is the active metabolite of Sulfasalazine (S699084), which is used for its anti-inflammatory properties, particularly in the treatment of gastrointestinal conditions.
Used in Anti-inflammatory Applications (Gastrointestinal):
Benzenesulfonic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-,
2,2-dimethylpropyl ester plays a role in the synthesis of mesalamine, which is utilized for its anti-inflammatory effects in the gastrointestinal tract. This makes it a valuable component in the development of medications for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis.

Upstream product

• 14248-15-8 4-bromo-benzenesulfonic acid 2,2-dimethylpropyl ester 
• 73183-34-3 bis(pinacol)diborane 
• 108-86-1 bromobenzene 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 75-84-3 2,2-dimethyl-propanol-1 

Downstream Products

• 1086957-30-3 4-(5-bromo-3,4-ethylenedioxythiophen-2-yl)benzenesulfonic acid 2,2-dimethylpropyl ester 
• 1086957-32-5 4-(5-(4-(dimethylamino)phenyl)-3,4-ethylenedioxythiophen-2-yl)benzenesulfonic acid 2,2-dimethylpropyl ester 
• 1086957-39-2 4-(5'-bromo-2,2'-bithiophen-5-yl)benzenesulfonic acid 2,2-dimethylpropyl ester 
• 1086957-27-8 4-(5-(4-(dimethylamino)phenyl)furan-2-yl)benzenesulfonic acid 2,2-dimethylpropyl ester 
• 1086957-20-1 4-(5-(4-(dimethylamino)phenyl)thiophen-2-yl)benzenesulfonic acid 2,2-dimethylpropyl ester 
• 1086957-25-6 4-(5-bromothiophen-2-yl)benzenesulfonic acid 2,2-dimethylpropyl ester 
• 1318251-85-2 4-(5-bromofuran-2-yl)benzenesulfonic acid 2,2-dimethylpropyl ester 
• 648905-69-5 4-{6-benzyloxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl}-benzenesulfonic acid 2,2-dimethyl-propyl ester 

Relevant academic research and scientific papers

Sky-blue-emitting cationic iridium complexes with oxadiazole/triazine-type counter-anions and their use for efficient solution-processed organic light-emitting diodes

Counter-anion control has emerged as a facile approach to tune the properties of cationic iridium complexes for optoelectronic applications. Here we report sky-blue-emitting cationic iridium complexes with electron-deficient oxadiazole/triazine-type count

Amphiphilic dendrimers control protein binding and corona formation on liposome nanocarriers

Amphiphilic polyphenylene dendrimers (PPDs) with distinct lipophilic and positively or negatively charged surface groups were adsorbed onto liposomes and their impact on protein adsorption in blood plasma was studied. The PPD corona reduced binding of spe

Synthesis and characterization of a mesogen-jacketed polyelectrolyte

In an attempt to construct a new kind of rodlike polyelectrolyte, poly[sodium 2,5-bis(4′-sulfophenyl)styrene] (PSBSS) was prepared from its precursor, poly[2,5-bis(4′-neopentylsulfophenyl)styrene] (PBNSS), which was polymerized by atom transfer radical polymerization. Small-angle X-ray scattering (SAXS) results demonstrate that PBNSS exhibits a hexagonal columnar phase and PSBSS exhibits a smectic A phase in bulk. The conformation of PSBSS in the aqueous solution is cylindrical, and the length and the diameter of the cylinder are ca. 25 nm and ca. 2.4 nm, respectively. The persistence length (lp) of the PSBSS chain in the aqueous solution is 11.50 ± 0.09 nm calculated by fitting the SAXS profile with the modified wormlike chain model. The conformation, the maximum length, and the lp of the chain are only weakly dependent on the concentration of the added salt. These results indicate that we have successfully obtained a new kind of polyelectrolyte with a highly rigid chain, a high charge density, and a narrow molecular weight distribution, which can serve as a new model macromolecule in studying rodlike polyelectrolytes.

SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.